Company Profile


BioRegenx, Inc. is redefining health intelligence with new patented technologies and artificial intelligence. We specialize in developing intellectual property (IP) and are engaged in regenerative biotherapeutics, anti-aging, artificial intelligence (AI) for healthcare and bioinformatics for public and private transportation. Our primary focus involves acquiring or developing non-invasive medical and wellness devices capable of efficiently recording, storing, and analyzing extensive datasets.

The current asset portfolio includes:

  • First-to-market, clinically relevant, patented technology for monitoring the endothelial glycocalyx and microvascular system.
  • A proprietary, patented formula that improves and protects the endothelial glycocalyx.
  • Artificial intelligence technology that enables contactless monitoring of vital health in just seconds.
Who We Are

Three patented technologies and solutions include:

  • GlycoCheck™: High-definition video imaging analyzes five parameters of microvascular health non-invasively with an under the tongue test using patented technology. Over 115 studies published.
  • Endocalyx Pro™: An all-natural, plant-based patented nutraceutical shown to restore, regenerate, and protect microvascular health. Clinically tested in multiple double-blind placebo studies.
  • DocSun™: Artificial Intelligence using three advanced facial recognition technologies that analyze 21 vital signs and health indicators without physical contact. Also used in private and public transportation.
Market Strategy

These products are sold with an effective direct-to-institution, direct-to-practitioner, direct-to-consumer sales model, and other emerging sales models that has BioRegenx poised to capture a significant portion of the global health and wellness market with technology and patents exclusive to BioRegenx.

Our Primary acquisition objective is to purchase technologies that are in the early stages of commercialization and generate revenue to leverage BioRegenx and its subsidiaries.


BioRegenx is a company focused on regenerative health solutions and proactive healthcare that enables people to live better lives. As a holding company, BioRegenx will capture market share by acquiring companies, products, and services on the leading edge of regenerative health and anti-aging.

Microvascular Health Solutions

MVHS is a research & development, sales, and marketing company that has developed the patented and clinically tested Endocalyx Pro™ dietary supplement.


NuLife Sciences

NuLife Sciences is a distribution company whose mission is to harness advanced technologies to redefine health and longevity.



MyBodyRx™ is a manufacturing, sales and product development company that produces dietary supplements that complement and work synergistically with the patented and clinically tested Endocalyx Pro™ product to support and improve healthy aging and increase longevity.

DocSun BioMedical Holdings, Inc.

DocSun BioMedical Holdings harnesses Artificial Intelligence (AI) and technology for non-invasive bodily monitoring and vital sign estimation.